Log in

Relevant bibliographies by topics / Refractory bullous pemphigoid / Journal articles

To see the other types of publications on this topic, follow the link: Refractory bullous pemphigoid.

Journal articles on the topic 'Refractory bullous pemphigoid'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Refractory bullous pemphigoid.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pratasava, Valeryia, Vikram N. Sahni, Aishwarya Suresh, et al. "Bullous Pemphigoid and Other Pemphigoid Dermatoses." Medicina 57, no. 10 (2021): 1061. http://dx.doi.org/10.3390/medicina57101061.

Full text

Abstract:

The pemphigoid family of dermatoses is characterized by autoimmune subepidermal blistering. The classic paradigm for pemphigoid, and the most common member, is bullous pemphigoid. Its variable clinical presentation, with or without frank bullae, is linked by significant pruritus afflicting the elderly. Mucous membrane pemphigoid is an umbrella term for a group of subepidermal blistering dermatoses that favor the mucosal membranes and can scar. Epidermolysis bullosa acquisita is a chronic blistering disorder characterized by skin fragility, sensitivity to trauma, and its treatment-refractory na

APA, Harvard, Vancouver, ISO, and other styles

2

D'Agostino, Giovanni Marco, Giulio Rizzetto, Andrea Marani, et al. "Bullous Pemphygoid and Novel Therapeutic Approaches." Biomedicines 10, no. 11 (2022): 2844. http://dx.doi.org/10.3390/biomedicines10112844.

Full text

Abstract:

Bullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately. Although it is a rare disease, bullous pemphigoid is the most common among the autoimmune bullous skin diseases. Systemic corticosteroids and immunosuppressants represent milestones in the treatment of patients suffering from bullous pemphigoid; however, therapeutic management of patients still represents a clinical challenge, owing to the chronic nature of the disease and to potential adverse effects related to the long-term use of

APA, Harvard, Vancouver, ISO, and other styles

3

Mereniuk, Eric, Laura Sabbah, and Jean-Paul Makhzoum. "A Case of Severe and Refractory Membranous Nephropathy Associated to Mucous Membrane Pemphigoid." Case Reports in Nephrology 2021 (May 11, 2021): 1–4. http://dx.doi.org/10.1155/2021/9940293.

Full text

Abstract:

Primary membranous nephropathy (MN) and mucous membrane pemphigoid (MMP) are two autoimmune conditions with well-defined diagnostic and treatment guidelines. MN has been linked to bullous pemphigoid (BP) in certain case reports, though little is known regarding the association of MN and other bullous diseases. The association of MN and MMP has rarely been described, and very little data exist regarding the treatment of this association. We report a case of severe refractory membranous nephropathy secondary to mucous membrane pemphigoid successfully treated with rituximab. A 35-year-old woman w

APA, Harvard, Vancouver, ISO, and other styles

4

Silva, Nuno, Andreia Costa, Fernando Salvador, and Elisa Serradeiro. "Penfigoide Bolhoso Tratado com Sucesso com Rituximab." Acta Médica Portuguesa 30, no. 3 (2017): 243. http://dx.doi.org/10.20344/amp.7812.

Full text

Abstract:

Bullous pemphigoid is an autoimmune disease characterized by subepidermal blister formation. Can be self-limiting but when necessary treatment includes the use of corticosteroids, immunosuppressants, and biological agents. We present the case of a 37 year old patient with a severe and refractory presentation of bullous pemphigoid. After about a month of treatment with various first line drugs and with no response, we chose to start rituximab and clear improvement of the lesions was observed. The authors aim to highlight the usefulness and effectiveness of this drug in this disease.

APA, Harvard, Vancouver, ISO, and other styles

5

Altmann, Stefanie, Dominique Jacobs, Thomas Brown, Preetha Kamath, and Karthik Krishnamurthy. "Treatment-Resistant Pemphigoid Following SARS-CoV-2 Vaccination." SKIN The Journal of Cutaneous Medicine 6, no. 3 (2022): 238–42. http://dx.doi.org/10.25251/skin.6.3.10.

Full text

Abstract:

As the SARS-CoV-2 vaccinated population increases, there have been many reports of vaccine-induced cutaneous reactions but scarce information on vaccine-induced autoimmune bullous disease. Vaccinations have been associated with the unmasking or development of autoimmune bullous disease; however, there is little data on SARS-CoV-2, specifically. We report a rare case of new-onset pemphigoid in a 70-year-old male following the second dose of the mRNA-1273 vaccine. The patient’s disease has been refractory to treatment, thus the underlying pathophysiology in vaccine-induced pemphigoid is likely u

APA, Harvard, Vancouver, ISO, and other styles

6

Uchida, Shusuke, Naoki Oiso, Hiroshi Koga, et al. "Refractory bullous pemphigoid leaving numerous milia during recovery." Journal of Dermatology 41, no. 11 (2014): 1003–5. http://dx.doi.org/10.1111/1346-8138.12650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

JENKINS, R. E., S. A. VAUGHAN JONES, and M. M. BLACK. "Conversion of pemphigoid gestationis to bullous pemphigoid- two refractory cases highlighting this association." British Journal of Dermatology 135, no. 4 (1996): 595–98. http://dx.doi.org/10.1046/j.1365-2133.1996.d01-1047.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

JENKINS, R. E., S. A. VAUGHAN JONES, and M. M. BLACK. "Conversion of pemphigoid gestationis to bullous pemphigoid— two refractory cases highlighting this association." British Journal of Dermatology 135, no. 4 (1996): 595–98. http://dx.doi.org/10.1111/j.1365-2133.1996.tb03838.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Thomsen, Kenneth, Mette Deleuran, Christian Vestergaard, Mette Holm, Rikke Riber-Hansen, and Rikke Bech. "Severe Infantile Bullous Pemphigoid Treated with Dapsone after Bridging with Systemic Glucocorticoid." Case Reports in Dermatology 11, no. 2 (2019): 187–93. http://dx.doi.org/10.1159/000501359.

Full text

Abstract:

We present a case of severe and treatment-refractory bullous pemphigoid in a 3-month-old child. After topical and systemic corticoid treatment proved inefficient, dapsone 0.75 mg/kg was added initially without success. Disease control was reached with dapsone 1.5 mg/kg in addition to both topical and systemic glucocorticoid treatment, leaving the child with several side effects of the glucocorticoid treatment.

APA, Harvard, Vancouver, ISO, and other styles

10

Bishnoi, Anuradha, Dipankar De, Sanjeev Handa, and Rahul Mahajan. "Biologics in autoimmune bullous diseases: Current scenario." Indian Journal of Dermatology, Venereology and Leprology 87 (July 1, 2021): 611–20. http://dx.doi.org/10.25259/ijdvl_886_19.

Full text

Abstract:

Autoimmune bullous diseases can be intraepidermal (pemphigus group of disorders) or subepidermal (pemphigoid group of disorders). The treatment of these disorders chiefly comprises corticosteroids and immunosuppressant adjuvants like azathioprine and mycophenolate mofetil. Autoantibodies are the main mediators of these diseases. Rituximab, a chimeric anti-CD20 monoclonal antibody targeting B-cells, has emerged as an excellent treatment option for refractory pemphigus vulgaris in the last decade. Since then, many new biologics have been proposed/explored for managing autoimmune bullous diseases

APA, Harvard, Vancouver, ISO, and other styles

11

Blanchard, G., K. Salamin, F. Solly, V. Basset, L. Fontao, and E. Guenova. "Treatment-refractory bullous pemphigoid in a patient with Sézary syndrome." European Journal of Cancer 173 (September 2022): S49. http://dx.doi.org/10.1016/s0959-8049(22)00650-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cruz, Maria João, Paulo Santos, Paulo Morais, Filomena Barreto, and Filomena Azevedo. "Refractory bullous pemphigoid with fatal outcome in a young patient." International Journal of Dermatology 52, no. 5 (2013): 601–2. http://dx.doi.org/10.1111/j.1365-4632.2011.05317.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

NAKAMA, Takekuni, Norito ISHII, Fumitake ONO, Takahiro HAMADA, Shinichiro YASUMOTO та Takashi HASHIMOTO. "Efficacy of interferon-γ in patients with refractory bullous pemphigoid". Journal of Dermatology 34, № 11 (2007): 737–45. http://dx.doi.org/10.1111/j.1346-8138.2007.00375.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hübner, F., M. Kasperkiewicz, D. Knuth-Rehr, et al. "490 Adjuvant immunoadsorption in severe and/or refractory bullous pemphigoid." Journal of Investigative Dermatology 137, no. 10 (2017): S276. http://dx.doi.org/10.1016/j.jid.2017.07.686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Wang, Qijun, Yue Ruan, Fei Guo, Haiqin Zhu, and Meng Pan. "Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid." Acta Dermato-Venereologica 103 (September 14, 2023): adv12324. http://dx.doi.org/10.2340/actadv.v103.12324.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Cardona, Andrés F., Alejandro Ruiz-Patiño, Zyanya Lucia Zatarain-Barron, et al. "Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab." Case Reports in Oncology 14, no. 1 (2021): 386–90. http://dx.doi.org/10.1159/000514144.

Full text

Abstract:

We present the case of a 73-year-old male patient with a history of tobacco use who presented with a central nervous system mass that was confirmed to be a lung adenocarcinoma metastasis. High PD-L1 expression as well as negativity to other targetable drivers led to initiation of pembrolizumab monotherapy and ablative stereotactic radiation therapy on oligoresidual disease, achieving a complete response after 2 years of therapy. Following discontinuation of systemic treatment, the patient developed widespread desquamative plaques. A skin biopsy revealed subepidermal blistering and eosinophili

APA, Harvard, Vancouver, ISO, and other styles

17

Hübner, Franziska, Michael Kasperkiewicz, Diana Knuth-Rehr, et al. "Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption." JDDG: Journal der Deutschen Dermatologischen Gesellschaft 16, no. 9 (2018): 1109–18. http://dx.doi.org/10.1111/ddg.13642.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Pereiro Jr, M., I. Suárez, B. Monteagudo, M. T. Abalde, D. Sánchez-Aguilar, and J. Toribio. "Alternariosis Refractory to Itraconazole in a Patient Suffering from Bullous Pemphigoid." Dermatology 202, no. 3 (2001): 268–70. http://dx.doi.org/10.1159/000051652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Pablo, Belmont Nava, Estefania Márquez-Maldonado Carol, Achell Nava Lucia, Maldonado Colin Guadalupe, and Maribel Arellano Vivero Dolores. "Successful Use of Dupilumab in Bullous Pemphigoid: A Series of 3 Cases in Mexico." International Journal of Medical Science and Clinical Research Studies 5, no. 03 (2025): 410–13. https://doi.org/10.5281/zenodo.14958236.

Full text

Abstract:

This review explores three recent case reports detailing the successful treatment of bullous pemphigoid (BP) with Dupilumab, a monoclonal antibody targeting interleukin-4 receptor alpha subunit (IL-4Rα). Each case highlights unique clinical presentations, treatment approaches, and outcomes, underscoring Dupilumab's potential as a therapeutic option in BP management.

APA, Harvard, Vancouver, ISO, and other styles

20

Fernández-Reynoso, Carla, Regina Canade Hernández-Hernández, Maribel Arellano-Vivero, Guadalupe Maldonado-Colín, Verónica Martínez-García, and Lucía Achell-Nava. "Multiimmunity Ratio in a Patient with Bullous Pemphigoid and Rheumatoid Arthritis." International Journal of Medical Science and Clinical Research Studies 05, no. 02 (2025): 371–77. https://doi.org/10.5281/zenodo.14934859.

Full text

Abstract:

Rheumatoid arthritis (RA) and bullous pemphigoid (BP) are autoimmune diseases influenced by genetic and environmental factors, with the concept of "shared autoimmune diathesis" suggesting that individuals with one autoimmune condition may be predisposed to developing another. This report describes a 62-year-old female with a 30-year history of untreated RA who presented with a progressive skin eruption initially misdiagnosed as herpes zoster. Over a four-month period, the patient developed pruritic bullous lesions predominantly in flexural areas. Histopathology and direct immunofluorescence co

APA, Harvard, Vancouver, ISO, and other styles

21

Yokoyama, R., R. Hayashi, Y. Umemori, A. Arimatsu, A. Yuki, and R. Abe. "Refractory bullous pemphigoid improved by discontinuation of phenytoin as an CYP3A4 inducer." Acta Dermato Venereologica 100, no. 8 (2020): adv00108–2. http://dx.doi.org/10.2340/00015555-3472.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Liang, Junqin, Kailibinuer Abulikemu, Maolidan, et al. "Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review." International Immunopharmacology 116 (March 2023): 109788. http://dx.doi.org/10.1016/j.intimp.2023.109788.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Konstadt, J. W. "Refractory bullous pemphigoid leading to respiratory arrest and successfully treated with plasmapheresis." Archives of Dermatology 126, no. 9 (1990): 1241–42. http://dx.doi.org/10.1001/archderm.126.9.1241.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Konstadt, Jody Weinflash. "Refractory Bullous Pemphigoid Leading to Respiratory Arrest and Successfully Treated With Plasmapheresis." Archives of Dermatology 126, no. 9 (1990): 1241. http://dx.doi.org/10.1001/archderm.1990.01670330121028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bambauer, Rolf, Daniel Burgard, and Ralf Schiel. "Therapeutic Apheresis in Dermatological Diseases." Clinical Medicine Insights: Therapeutics 7 (January 2015): CMT.S14112. http://dx.doi.org/10.4137/cmt.s14112.

Full text

Abstract:

Since the mid-1970s, membrane modules became available and plasma separation techniques have gained importance. Therapeutic apheresis (TA) has been successfully introduced in a variety of autoantibody-mediated diseases. In dermatology, TA is increasingly applied as a support treatment for severe and/or refractory autoimmune bullous diseases. All autoimmune disease are characterized by autoantibodies mediated against structural proteins of the skin and/or mucous membranes. Autoimmune blistering diseases have a high morbidity and mortality. These diseases include pemphigus vulgaris and bullous p

APA, Harvard, Vancouver, ISO, and other styles

26

Bilgiç Temel, Aslı, Cumhur Ibrahim Bassorgun, Ayşe Akman-Karakaş, Erkan Alpsoy, and Soner Uzun. "Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments." Case Reports in Dermatology 9, no. 1 (2017): 38–44. http://dx.doi.org/10.1159/000452828.

Full text

Abstract:

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. A specific protocol for the use of rituximab to treat BP patients is not yet available. There are only small case series and case reports about the efficacy and safety of rituximab in BP. Here we present a you

APA, Harvard, Vancouver, ISO, and other styles

27

Liang, J., K. Abulikemu, M. Lidan, et al. "116 Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review." Journal of Investigative Dermatology 143, no. 5 (2023): S20. http://dx.doi.org/10.1016/j.jid.2023.03.117.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Afarideh, Mohsen, Robert Borucki, and Victoria P. Werth. "A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets." Journal of Clinical Medicine 11, no. 10 (2022): 2856. http://dx.doi.org/10.3390/jcm11102856.

Full text

Abstract:

Bullous pemphigoid (BP) is a rare, chronic antibody-mediated autoimmune blistering disease primarily affecting the elderly, with an age of onset over 60. Current treatment options are limited and involve the use of corticosteroids and immunosuppressants, but their long-term use is associated with significant morbidity and mortality. In Japan, human intravenous immunoglobin is approved for the treatment of corticosteroid-refractory BP. However, no treatment option is approved by the Food and Drug Administration for the management of BP. Therefore, developing effective therapies free of debilita

APA, Harvard, Vancouver, ISO, and other styles

29

DAA, Yamato, Tamaki KOMORI, Kaori KAWAKAMI, et al. "A Case of Refractory Bullous Pemphigoid Complicated by Atopic Dermatitis Successfully Treated with Dupilumab." Nishinihon Journal of Dermatology 86, no. 1 (2024): 26–29. http://dx.doi.org/10.2336/nishinihonhifu.86.26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Granados-Betancort, Elena, Manuel Sánchez-Díaz, Daniel Muñoz-Barba, and Salvador Arias-Santiago. "Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review." Journal of Clinical Medicine 13, no. 16 (2024): 4844. http://dx.doi.org/10.3390/jcm13164844.

Full text

Abstract:

Background: Bullous pemphigoid (BP) is an autoimmune disease characterized by the appearance of very pruritic subepidermal blisters. It appears mostly in the elderly and is associated with multiple comorbidities, which makes its management and treatment difficult. The purpose of this systematic review is to compile current information on published cases of BP treated with omalizumab (omalizumab) and dupilumab (dupilumab) in order to obtain information on clinical efficacy and safety data available. Methods: A literature search of all cases of BP treated with omalizumab/dupilumab published in t

APA, Harvard, Vancouver, ISO, and other styles

31

Altan Ferhatoglu, Zeynep, Sera Nur Yucesoy, Tumay Ak, and Yusuf Demir. "Omalizumab in the treatment of bullous pemphigoid: A single-center series of 15 cases." Medicine 103, no. 30 (2024): e38684. http://dx.doi.org/10.1097/md.0000000000038684.

Full text

Abstract:

Bullous pemphigoid (BP) is a chronic autoimmune disease affecting the elderly population and characterized by the formation of subepidermal tense bullae. Treatment options include topical steroids, systemic steroids, immunosuppressants, and antimicrobials, and there is emerging evidence of the efficacy of omalizumab. In this study, we aimed to demonstrate omalizumab’s efficacy for treating BP, and we also reported treatment-related adverse events. The retrospective cohort study included patients with BP who were followed up in our clinic’s bullous diseases department between 2016 and 2023. Pat

APA, Harvard, Vancouver, ISO, and other styles

32

Lomax, Anna J., Jennifer Lim, Robert Cheng, et al. "Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management." Journal of Skin Cancer 2018 (2018): 1–13. http://dx.doi.org/10.1155/2018/9602540.

Full text

Abstract:

Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) are a standard of care for advanced melanoma. Novel toxicities comprise immune-related adverse events (irAE). With increasing use, irAE require recognition, practical management strategies, and multidisciplinary care. We retrospectively evaluated the incidence, kinetics, and management of irAE in 41 patients receiving anti-PD-1 antibody therapy (pembrolizumab) for advanced melanoma. 63% received prior anti-CTLA-4 antibody therapy (ipilimumab). IrAE occurred in 54%, most commonly dermatological (24%), rheumatological (22%), and

APA, Harvard, Vancouver, ISO, and other styles

33

Sarrazin, M., F. Jouen, and S. Duvert-Lehembre. "Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab." Annales de Dermatologie et de Vénéréologie 148, no. 1 (2021): 60–62. http://dx.doi.org/10.1016/j.annder.2020.08.053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Sardana, Kabir, Surabhi Sinha, Diksha Agrawal, Anita Kulhari, and Purnima Malhotra. "Complete remission in a patient with treatment refractory bullous pemphigoid after a single dose of omalizumab." Indian Dermatology Online Journal 11, no. 4 (2020): 607. http://dx.doi.org/10.4103/idoj.idoj_438_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ogawa, Yasushi, Ayumi Adachi, Miyako Okamoto, Takashi Hashimoto, and Yasushi Tomita. "A Case of Refractory Bullous Pemphigoid with Plasmapheresis-Associated Thrombopenia: Efficacy of Pulsed Intravenous Cyclophosphamide Therapy." Journal of Dermatology 31, no. 8 (2004): 651–54. http://dx.doi.org/10.1111/j.1346-8138.2004.tb00571.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Ronaghy, Arash, Robert D. Streilein, and Russell P. Hall. "Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP)." Journal of Dermatological Science 74, no. 1 (2014): 93–94. http://dx.doi.org/10.1016/j.jdermsci.2013.11.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Pham, H., D. Lanoue, J. Valois, and W. Yang. "M557 SUCCESSFUL TREATMENT AND COMPLETE STEROID SPARING USING OMALIZUMAB IN BULLOUS PEMPHIGOID MASQUERADING AS REFRACTORY URTICARIA." Annals of Allergy, Asthma & Immunology 125, no. 5 (2020): S115. http://dx.doi.org/10.1016/j.anai.2020.08.384.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Leibovit-Reiben, Z., A. L. Stockard, N. Zhang, et al. "0449 Identifying clinical and molecular phenotypes in bullous pemphigoid and immune checkpoint inhibitor-induced bullous pemphigoid: A hierarchical clustering on principal components analysis identifies unique phenotypes and treatment refractory subsets." Journal of Investigative Dermatology 145, no. 8 (2025): S77. https://doi.org/10.1016/j.jid.2025.06.454.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Lee, Yin Yin, Ping Chong Bee, Chew Kek Lee, Manimalar Naiker, and Rokiah Ismail. "Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast." Annals of Dermatology 23, Suppl 3 (2011): S390. http://dx.doi.org/10.5021/ad.2011.23.s3.s390.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gardner, Jennifer M. "Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma." Archives of Dermatology 145, no. 9 (2009): 985. http://dx.doi.org/10.1001/archdermatol.2009.229.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ding, Shu, Qiancheng Deng, Yaping Xiang, Jing Chen, Jinhua Huang, and Jianyun Lu. "Bullous pemphigoid associated with milia, increased serum IgE, autoantibodies against desmogleins, and refractory treatment in a young patient." Anais Brasileiros de Dermatologia 92, no. 5 suppl 1 (2017): 34–36. http://dx.doi.org/10.1590/abd1806-4841.20176124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Takata, Mayumi, Shunya Usui, Toshiaki Kogame, Atsushi Otsuka, and Kenji Kabashima. "Mucous membrane pemphigoid involving palmoplantar lesions that developed during adjuvant nivolumab for malignant melanoma: A rare case and literature review." Trends in Immunotherapy 7, no. 2 (2023): 2779. http://dx.doi.org/10.24294/ti.v7.i2.2779.

Full text

Abstract:

Immune checkpoint inhibitors (ICIs), such as nivolumab, which target anti‐programmed cell death-1 (PD-1), have been applied to a variety of cancers and have caused immune‐related adverse events (irAEs). Although an association between ICIs and bullous pemphigoid and mucosal pemphigoid (MMP) has been reported, the complex mechanisms underlying PD-1 inhibition‐induced autoantibody production and autoimmunity remain unelucidated. In this report, we present a unique case of MMP involving the palmoplantar lesions during adjuvant nivolumab therapy. A Japanese woman in her 70s was treated with nivolu

APA, Harvard, Vancouver, ISO, and other styles

43

Thewjitcharoen, Yotsapon, Ekgaluck Wanothayaroj, Chattip Thammawiwat, et al. "Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients." Case Reports in Endocrinology 2020 (October 10, 2020): 1–6. http://dx.doi.org/10.1155/2020/8832643.

Full text

Abstract:

The use of dipeptidyl peptidase-4 inhibitors (DPP4i) appears to be associated with a small but significantly elevated risk of bullous pemphigoid (BP). Although the pathogenic mechanism of DPP4i-associated BP remains unclear, this adverse event is reported with multiple gliptins, suggesting a class effect. However, previous studies from various countries showed that vildagliptin had been implicated in most cases. The aim of this study was to illustrate a case series of DPP4i-associated BP in Thai patients. We conducted a retrospective study from consecutive cases of BP in people with type 2 dia

APA, Harvard, Vancouver, ISO, and other styles

44

Pai, Sara, Douglas Adkins, Lori Wirth, et al. "354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A379. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0354.

Full text

Abstract:

BackgroundImmuno-STATsTM are novel, modular fusion proteins designed to selectively activate tumor-antigen-specific CD8+ T cells. Human papillomavirus (HPV) associated cancers serve as a model system to assess the safety and efficacy of the Immuno-STAT platform. CUE-101 is comprised of human leukocyte antigen (HLA) complex, HLA A*0201, a peptide epitope derived from the HPV type 16 E7 protein, and 4 molecules of a reduced affinity human interleukin-2 (IL2) designed to bind and activate HPV-specific T cells for eradication of HPV16-driven cancers. In preclinical studies CUE-101 demonstrated sel

APA, Harvard, Vancouver, ISO, and other styles

45

Zhou, Tong, Bin Peng, and Songmei Geng. "Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid." Frontiers in Immunology 12 (August 24, 2021). http://dx.doi.org/10.3389/fimmu.2021.718073.

Full text

Abstract:

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder in the elderly. Systemic and topical use of glucocorticoids and immunosuppressants has been shown to be effective in most patients. However, refractory BP patients are challenged to clinicians with severe clinical symptoms, resistance to treatment, and high relapse rate. How to predict and assess the refractory and severity of bullous pemphigoid is the key issue in clinical practice, and the urgent need for precision medicine in refractory patients is driving the search for biomarkers and biologics. Recently

APA, Harvard, Vancouver, ISO, and other styles

46

Blanchard, Gabriela, Francoise Solly, Valentin Basset, Lionel Fontao, Maël Blanchard, and Emmanuella Guenova. "Vorinostat for treatment‐refractory bullous pemphigoid." Journal of the European Academy of Dermatology and Venereology, May 16, 2023. http://dx.doi.org/10.1111/jdv.19209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Shrestha, Prajwol, Mathew K. George, Sweta Baidya, and Sunil K. Rai. "Bullous pemphigoid associated with squamous cell lung carcinoma showing remarkable response to carboplatin-based chemotherapy: a case report." Journal of Medical Case Reports 16, no. 1 (2022). http://dx.doi.org/10.1186/s13256-022-03323-9.

Full text

Abstract:

Abstract Background Bullous pemphigoid is an uncommon dermatologic manifestation seen in squamous cell lung cancer, and evidence guiding optimal treatment, especially in the elderly population, is limited. We report herein a case of squamous cell lung cancer diagnosed after being investigated for refractory bullous pemphigoid showing marked response to carboplatin-based chemotherapy. This is the first case report that shows carboplatin can be used as an effective alternative in treatment of malignancy-associated bullous pemphigoid. Case report An 80-year-old caucasian man developed extensive v

APA, Harvard, Vancouver, ISO, and other styles

48

Alexandre, Marina, Gérôme Bohelay, Thomas Gille, et al. "Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients." Frontiers in Immunology 13 (April 20, 2022). http://dx.doi.org/10.3389/fimmu.2022.874108.

Full text

Abstract:

The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid efficacy and allowing significant improvements or complete remission as add-on therapy in first-line treatment-resistant patients. Herein, we report the largest retrospective study to evaluate OMZ effectiveness in patients with subepidermal autoimmune blistering diseases. Our series included 13 pat

APA, Harvard, Vancouver, ISO, and other styles

49

Xiao, Yue, Yuanxia Gu, Dengmei Xia, Xingli Zhou, and Wei Li. "Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid." Journal of Dermatology, August 26, 2022. http://dx.doi.org/10.1111/1346-8138.16559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Fukushima, Yuki, Youichi Ogawa, Riko Asakawa, et al. "Case of Severe Bullous Pemphigoid Refractory to Rituximab." Journal of Dermatology, June 6, 2025. https://doi.org/10.1111/1346-8138.17815.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!